stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Net income
Cogent Biosciences, Inc.'s net income for fiscal 2025 was −$328.9M, compared with −$255.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$377.2M. Over the past ten years it has ranged from −$328.9M (fiscal 2025) to −$6.6M (fiscal 2015) — the current reading is the lowest in ten years. Net income has fallen for 4 consecutive fiscal years. Cogent Biosciences, Inc. ranks 571st of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$328.9M | — |
| FY2024 | −$255.9M | — |
| FY2023 | −$192.4M | — |
| FY2022 | −$140.2M | — |
| FY2021 | −$72.3M | — |
| FY2020 | −$74.8M | — |
| FY2019 | −$31.8M | — |
| FY2018 | −$34.5M | — |
| FY2017 | −$25.5M | — |
| FY2016 | −$18.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$96.4M | — |
| Mar 2026 | −$97.4M | — |
| Dec 2025 | −$102.5M | — |
| Sep 2025 | −$80.9M | — |
| 36 more quarters | Free account |
Against its own ten years
Low −$328.9M
High −$6.6M
Ten-year median
−$72.3M
Current reading's percentile
9
Net income against peers
| Company | Net income |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | −$106.0M |
| TVTX Travere Therapeutics, Inc. compare | −$121.5M |
| MANE Veradermics Incorporated compare | −$136.4M |
| DNTH Dianthus Therapeutics, Inc. compare | −$202.1M |
| KOD Kodiak Sciences Inc. compare | −$242.0M |
| ERAS Erasca, Inc. compare | −$287.2M |
| COGT Cogent Biosciences, Inc. | −$377.2M |
| SRRK Scholar Rock Holding Corporation compare | −$408.6M |
| CRSP CRISPR Therapeutics AG compare | −$456.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on COGT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement